Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Aardvark Therapeutics, Inc. (AARD:NASDAQ), powered by AI.
Aardvark Therapeutics, Inc. is currently trading at $3.72. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Aardvark Therapeutics, Inc. on Alpha Lenz.
Aardvark Therapeutics, Inc.'s P/E ratio is -1.3.
“Aardvark Therapeutics, Inc. trades at a P/E of -1.3 (undervalued) with modest ROE of -221.5%.”
Ask for details →Aardvark Therapeutics Inc. operates within the dynamic healthcare industry, focusing on the development and commercialization of innovative therapeutics. The primary goal of Aardvark Therapeutics is to address significant unmet needs in medical treatments, advancing the landscape of healthcare through scientific discovery and technological advancement. With a strong emphasis on research and development, the company is engaged in creating a pipeline of products that offer novel approaches to treating various health conditions. These efforts can have far-reaching impacts across multiple sectors within the industry, including biopharmaceuticals and biotechnology. Aardvark Therapeutics Inc. plays a critical role in the market by driving forward the possibilities of next-generation therapies, contributing to both patient outcomes and healthcare system advancements. As the company seeks to bring transformative solutions to market, its activities are closely monitored by stakeholders interested in the progression of medical science and its applicability to everyday health challenges.
“Aardvark Therapeutics, Inc. trades at a P/E of -1.3 (undervalued) with modest ROE of -221.5%.”
Ask for details →Aardvark Therapeutics, Inc. (ticker: AARD) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 31 employees. Market cap is $73M.
The current price is $3.72 with a P/E ratio of -1.27x and P/B of 0.68x.
ROE is -221.55%.